Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsoninan flatworm model

Journal of Pharmacological Sciences

Volumn 92, Issue 2, 2003, Pages 137-142

  Kitamura, Yoshihisa ^a   Inden, Masatoshi ^a   Sanada, Hisakuza ^a   Takata, Kazuyuki ^a   Taniguchi, Takashi ^a   Shimohama, Shun ^b   Orii, Hidehumi ^c   Mochii, Makoto ^c   Agata, Kiyokazu ^d   Watanabe, Kenji ^c  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF HYOGO   (Japan)

^d RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

Antiparkinsonian drug; Caspase inhibitor; MPTP; Parkinsonian flatworm model; Rotenone

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ANTIPARKINSON AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLASPARTYLMETHYL 2,6 DICHLOROBENZENE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; CLORGYLINE; DOPAMINE; N (2 AMINOETHYL) 4 CHLOROBENZAMIDE; NOMIFENSINE; PRAMIPEXOLE; ROTENONE; TALIPEXOLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLYSIS; CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DNA DEGRADATION; DOPAMINERGIC SYSTEM; DRUG EFFECT; ENZYME ACTIVATION; GASTROINTESTINAL TRACT; INHIBITION KINETICS; INVERTEBRATE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PLATYHELMINTH; PROTECTION; TIME;

EID: 10744225603     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.92.137     Document Type: Article

References (37)

1. Dunnett SB, Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 1999;Suppl:A32-A39.
2. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 1999;22:123-144.
3. Davis GC, Williams AC, Markey SP, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res. 1979;1:249-254.
4. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301-1306.
6. Sarnat HB, Netsky MG. The brain of planarian as the ancestor of the human brain. Can J Neurol Sci. 1985;12:296-302.
7. Kato K, Orii H, Watanabe K, Agata K. The role of dorsoventral interaction in the onset of planarian regeneration. Development. 1999;126:1031-1040.
8. Orii H, Kato K, Umesonmo Y, Sakurai T, Agata K, Watanabe K. The planarian HOM/HOX homeobox genes (Plox) expressed along the anteroposterior axis. Dev Biol. 1999;210:456-468.
9. Saló E, Baguñà J. Regeneration in planarians and other worms: New findings, new tools, and new perspectives. J Exp Zool. 2002;292:528-539.
10. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol. 1997;74;51-57.
11. Kitamura Y, Kosaka T, Kakimura J, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1998;54:1046-1054.
12. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T. Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol. 2001;417:59-67.
13. Kitamura Y, Kakimura J, Taniguchi T. Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model. Jpn J Pharmacol. 1998;78:23-29.
14. Agata K, Watanabe K. Molecular and cellular aspects of planarian regeneration. Semin Cell Dev Biol. 1999;10:377-383.
15. Venturini G, Stocchi F, Margotta V, et al. Pharmacological study of dopaminergic receptors in planaria. Neuropharmacology. 1989;28:1377-1382.
16. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394-398.
17. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science. 2000;287:1265-1269.
18. Haass C, Kahle PJ. Parkinson's pathology in a fly. Nature. 2000;404:341-342.
19. Kitamura Y, Shimohama S, Akaike A, Taniguchi T. The parkinsonian models: Invertebrates to mammals. Jpn J Pharmacol. 2000;84:237-243.
20. Pendleton RG, Parvez F, Sayed M, Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Ther. 2000;300:91-96.
21. Nass R, Miller III DM, Blakey RD. C elegans: A novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord. 2001;7:185-191.
22. Nass R, Hall DH, Miller III DM, Blakey RD. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2002;99:3264-3269.
23. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;I:1269.
24. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun. 1989;163:1450-1455.
25. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA. 2000;97:2875-2880.
26. Sriram K, Pai KS, Boyd MR, Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies in mice. Brain Res. 1997;749:44-52.
27. Hagan JJ, Middlemiss DN, Sharpe PC, Poste GH. Parkinson's disease: Prospects for improved drug therapy. Trends Pharmacol Sci. 1997;18:156-163.
28. Kitamura Y, Kakimura Y, Taniguchi T. Antiparkinsonian drugs and their neuroprotective effects. Biol Pharm Bull. 2002;25:284-290.
29. Parkinson study group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J Am Med Assoc. 2002;287:1653-1661.
30. Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenabeele P. Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Cell Death Differ. 2002;9:358-361.
31. Zou H, Henzel J, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405-413.
32. Bowen ID, Den Hollander JE, Lewis GHJ. Cell death and acid phosphatase activity in the regenerating planarian Polycelis tenuis Iijima. Differentiation. 1982;21:160-167.
33. Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm. 2001;108:1263-1282.
34. Gage FH. Mammalian neural stem cells. Science. 2000;287:1433-1438.
35. Björklund LM, Sánchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 2002;99:2344-2349.
36. Agata K, Soejima Y, Kato K, Kobayashi C, Umesono Y, Watanabe K. Structure of the planarian central nervous system (CNS) revealed by neuronal cell markers. Zool Sci. 1998;15:433-440.
37. Cebrià F, Kobayashi C, Umesono Y, et al. FGFR-related gene nou-darake restricts brain tissues to the head region of planarians. Nature. 2002;419:620-624.